about
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastCytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunityAutoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management.Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis.Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization.Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions.Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severityGenome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2Luteolin inhibits human keratinocyte activation and decreases NF-κB induction that is increased in psoriatic skin.Cutting edge: NF-κB p65 and c-Rel control epidermal development and immune homeostasis in the skinFirst-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis.Getting under the skin: the immunogenetics of psoriasis.Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cellsRecommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus.Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research.CCR6 as a possible therapeutic target in psoriasis.Psoriasis vulgaris and familial cancer risk- a population-based study.Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations.Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasisProkineticin 2 Plays a Pivotal Role in Psoriasis.Common variants of ZNF750, RPTOR and TRAF3IP2 genes and psoriasis risk.Targeting signaling pathways with small molecules to treat autoimmune disorders.Amygdalin analogs for the treatment of psoriasis.Apremilast for the treatment of psoriatic arthritis.Genomic-scale analysis of psoriatic skin reveals differentially expressed insulin-like growth factor-binding protein-7 after phototherapy.Unleashing the therapeutic potential of human kallikrein-related serine proteases.IL-35 Decelerates the Inflammatory Process by Regulating Inflammatory Cytokine Secretion and M1/M2 Macrophage Ratio in Psoriasis.Treatment of psoriasis with etanercept: the typical patient profile.Isoliquiritigenin prevents the progression of psoriasis-like symptoms by inhibiting NF-κB and proinflammatory cytokines.Development and validation of human psoriatic skin equivalents.Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study.Topical anti-inflammatory activity of Eugenia brasiliensis Lam. (Myrtaceae) leaves.Ustekinumab for the treatment of psoriatic arthritis.Scanning the Immunopathogenesis of Psoriasis.Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy
P2860
Q22305855-4F87DACF-CD6B-49B1-B1B9-1F47E95E655BQ22306446-55129026-8164-4060-909E-A81BA463A7B9Q30245322-6BD95A01-9B29-4806-9E98-5391EEF16DA6Q30373501-35E90760-6673-409A-BBD6-88765ABE996AQ33278998-0E176E10-69C7-4E3B-9B63-7AACA5FAC2DEQ34091087-A41B6804-30C3-4AD2-BF27-38C04E7FDDC6Q34428875-B259B1FC-6A37-454B-B12F-0E7CB8C710E7Q34945351-67FA4A83-8EF1-488F-BA5F-B77943131CF1Q35105452-30769D30-3E1E-439A-BC3A-0E775FA265E8Q35109173-F88CFD9A-91BA-45DF-9687-38BCE10ADEE4Q35163927-1713DAB4-AA61-418A-A092-08CD437B71ACQ35739806-B9E605CF-FC2E-42EE-B398-CF22C03D2536Q36247085-5B2A6F8F-EAD3-4626-8BCA-FA4C0DE587FFQ36401164-6BBFEDE2-F6B2-4276-BA3F-75EBE0BFFCA5Q36572788-964DA9E5-A4D9-4247-BB15-BEB1A2E524C5Q36917184-845CE89F-2E7B-4BCA-97DD-C9843ED083E7Q36980670-FC7E74FA-4478-47C5-88ED-38DD7CBC86F7Q36985655-A6E0076D-3E5C-4D41-A2A5-428148623B24Q37125441-E1DC1F6C-03EE-4F9E-8317-7ED68F78FA50Q37592632-3A3DF9FC-3E07-4B60-A5E4-4660939CEFE5Q37604630-9B8D6D58-1670-4690-A981-6B4F5DC37B1EQ37638886-ABC43740-9863-4E2D-96E8-9631FAAA18CBQ37755216-9CBCAFE7-C275-47F2-B8E8-D5871D8E5A09Q38104754-09204255-3986-4FC9-8586-EC496E1B954FQ38202205-CA306ACB-8E35-4486-8B98-70C678AC8642Q38305758-BAF4117E-0D7B-406C-B77D-7B4E8DA2F439Q38362486-6F686219-D17C-445B-8B85-C8001AC00F1CQ38751686-7A012200-BCB4-405E-87C2-11BE59F00784Q38807058-F23CFBB5-6589-4622-830E-D92E8C4A83D6Q38834387-9B8B9030-1740-4AC7-8BB0-F3CB8E0B8F3BQ42423385-D59E7678-4BD8-423B-B953-59153DD7270AQ42756894-26B2E108-A7F8-45A7-97B7-97AF9F08D33CQ46670556-A7B2E53D-A80A-464C-AC66-92BFF19ADDB6Q48086737-9F5B269E-CBC5-4CC1-81D9-82C9113C9BCBQ48278167-50147458-FAA9-49F7-9FEC-BFE5F0603FFEQ54262278-9118E750-89DA-4763-969E-85CD53458227Q57941543-01D96B3A-6C97-42A6-A057-1E3BAA26B088
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Psoriasis: emerging therapeutic strategies.
@ast
Psoriasis: emerging therapeutic strategies.
@en
type
label
Psoriasis: emerging therapeutic strategies.
@ast
Psoriasis: emerging therapeutic strategies.
@en
prefLabel
Psoriasis: emerging therapeutic strategies.
@ast
Psoriasis: emerging therapeutic strategies.
@en
P2860
P356
P1476
Psoriasis: emerging therapeutic strategies.
@en
P2093
Alice B Gottlieb
P2860
P2888
P356
10.1038/NRD1607
P577
2005-01-01T00:00:00Z
P6179
1020590823